ACLARION NEW DL-,00001 Aktie

Aclarion shares rose sharply in premarket trading after the Nociscan platform’s scan volume increased 114% year‑over‑year in Q4 2025; annual volume grew 69% in 2025. The company expanded its commercial network in 2025 by nine imaging centers and 22 physician users, reported four new patents (52 in total), and held $12.0 million in cash with no debt. Aclarion raised $22.0 million in equity financing (cash runway through 2027), aims to enroll about 25% of patients into the CLARITY study by the end of Q2 2026, and plans to expand partnerships with MRI manufacturers to grow the market by >30%. » More on de.investing.com

Aclarion shares rose 6.3% in premarket trading after the Nociscan solution was featured in a pain special issue of the International Journal of Spine Surgery. The tech-update article sponsored by Aclarion describes the use of biomarkers and AI for non-invasive localization of chronic lumbar spine pain and includes a case example with a successful single-level treatment. Aclarion positions Nociscan as the first evidence-based SaaS platform to differentiate painful from non-painful discs and targets the estimated 266 million people worldwide affected by low back pain. » More on de.investing.com

Aclarion appoints Dan Isherwood as commercial director for Great Britain to drive the commercial rollout of Nociscan technology. Three of the four largest private health insurers now cover the costs, giving over 5.2 million insured people access and making the UK the first market where Nociscan is free at point of care. The company reports a Q3 scan volume increase of 89% year-over-year, a debt-free balance sheet with $13.3 million in cash, and the appointment of Greg Gould as CFO. Ascendiant Capital raised its price target for Aclarion to $22 and maintained its "Buy" rating. » More on de.investing.com